NCCN Task Force report: Breast cancer in the older woman

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue SUPPL. 4, 2008, Pages

  Carlson, Robert W ^a   Moench, Susan ^a   Hurria, Arti ^a   Balducci, Lodovico ^a   Burstein, Harold J ^a   Goldstein, Lori J ^a   Gradishar, William J ^a   Hughes, Kevin S ^a   Jahanzeb, Mohammad ^a   Lichtman, Stuart M ^a   Marks, Lawrence B ^a   McClure, Joan S ^a   McCormick, Beryl ^a   Nabell, Lisle M ^a   Pierce, Lori J ^a   Smith, Mary Lou ^a   Topham, Neal S ^a   Traina, Tiffany A ^a   Ward, John H ^a   Winer, Eric P ^a  

^a NONE

Author keywords

Breast cancer; Breast cancer mortality; Chemotherapy; Comorbidity; Functional reserve; Geriatric assessment; Life expectancy; NCCN Clinical Practice Guidelines; Older woman; Physiologic reserve; Treatment; Tumor biology

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; AGE DISTRIBUTION; ARTHRALGIA; ATTITUDE; BIOLOGY; BLOOD TOXICITY; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; ENDOMETRIUM CARCINOMA; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MEDICAL SPECIALIST; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PARTIAL MASTECTOMY; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PLASTIC SURGERY; REVIEW; SIDE EFFECT; SOCIAL SUPPORT; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; AGE; AGED; BREAST NEOPLASMS; FEMALE; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; PATHOLOGY; PATIENT CARE; UNITED STATES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE TEAM; UNITED STATES;

EID: 47349113208     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Surveillance Epidemiology and End Results (SEER). National Cancer Institute. Available at: http://seet.cancer.gov. Accessed: April 8, 2008.
2. U.S. Census Bureau. Available at: http://www.census.gov/prod/2006pubs/ p23-209.pdf. Accessed: April 8, 2008.
3. Centers for Disease Control and Prevention (CDC). Department of Health and Human Services. Available at: www.cdc.gov. Accessed: April 10, 2008.
4. Crivellari D, Aapro M, Leonard R, et al. Breast cancer in the elderly. J Clin Oncol 2007;25:1882-1890.
5. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858-1869.
6. Witherby SM, Muss HB. Managing early-stage breast cancer in your older patients. Oncology (Williston Park) 2006;20:1003-1012; discussion 1012-1013, 1017-1018.
7. Carlson RW, Anderson BO, Burstein HJ, et al. NCCN clinical practice guidelines in oncology: invasive breast cancer. J Natl Compr Canc Netw 2007;5:246-312.
8. Balducci L, Baskin R, Cohen HJ, et al. The NCCN Senior Adult Oncology Guidelines, version 2, 2007. Available at: http://www.nccn.org/physician_gls/ index.html. Accessed: April 9, 2008.
9. Balducci L, Cohen HJ, Engstrom PF, et al. NCCN clinical practice guidelines in oncology: senior adult oncology. J Natl Compr Canc Netw 2005;3:572-590.
10. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 2007;14:7-12.
11. Kanonidou Z, Karystaianou G. Anesthesia for the elderly. Hippokratia 2007;11:175-177.
12. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006;24:1846-1851.
13. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-1077.
14. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
15. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007;14:44-56.
16. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
17. Beex LV, Hermus AR, Pieters GF, et al. Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer. Eur J Cancer 1992;28:686-690.
18. Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 2007;14:32-43.
19. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283.
20. Koroukian SM, Murray P, Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care. J Clin Oncol 2006;24:2304-2310.
21. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007;25:3699-3704.
22. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92.
23. Rastogi P, Jeong J, Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract LBA 513.
24. Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004;30:333-342.
25. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
26. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
27. Extermann M. Treating advanced breast cancer in the older woman. Oncology (Williston Park) 2006;20:1355-1360; discussion 1360, 1362, 1367-1358.
28. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-1979.
29. Arias E. National Vital Statistics Report: United States Life Tables, 2003. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdf. Accessed April 9, 2008.
30. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-1717.
31. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
32. Centers for Disease Control and Prevention (CDC). Department of Health and Human Services. Available at: http://www.cdc.gov/cancer/breast/statistics/ age.htm. Accessed: April 8, 2008.
33. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224-237.
34. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 2004;96:1311-1321.
35. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-1081.
36. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years or older with breast cancer. N Engl J Med 2004;351:971-977.
37. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up [abstract]. Presented at the San Antonio Breast Cancer Symposium; San Antonio, Texas; December 14-17, 2006. Abstract 11.
38. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
39. Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683-1690.
40. Rockwood K, Stadnyk K, MacKnight C, et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999;353:205-206.
41. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-1699.
42. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-1831.
43. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148.
44. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-156.
45. Hurria A, Lachs MS, Cohen HJ, et al. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol 2006;59:211-217.
46. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005;104:1998-2005.
47. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
48. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801-808.
49. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
50. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34.
51. Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007;18:1314-1321.
52. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007;110:1376-1384.
53. Rimon E, Kagansky N, Cojocaru L, et al. Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients? QJM 2004;97:281-287.
54. Pedone C, Corsonello A, Incalzi RA. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006;35:121-126.
55. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 2003;114:180-187.
56. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 2005;105:2294-2299.
57. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
58. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
59. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.
60. Figueiredo MI, Cullen J, Hwang YT, et al. Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health? J Clin Oncol 2004;22:4002-4009.
61. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994;86:1766-1770.
62. Husain LS, Collins K, Reed M, Wyld L. Choices in cancer treatment: a qualitative study of the older women's (> 70 years) perspective. Psychooncology 2008;17:410-416.
63. Ciambrone D. Treatment decision-making among older women with breast cancer. J Women Aging 2006;18:31-47.
64. Kreling B, Figueiredo MI, Sheppard VL, Mandelblatt JS. A qualitative study of factors affecting chemotherapy use in older women with breast cancer: barriers, promoters, and implications for intervention. Psychooncology 2006;15:1065-1076.
65. Maly RC, Leake B, Silliman RA. Breast cancer treatment in older women: impact of the patient-physician interaction. J Am Geriatr Soc 2004;52:1138-1145.
66. Liang W, Burnett CB, Rowland JH, et al. Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol 2002;20:1008-1016.
67. Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 2004;101:1302-1310.
68. Mustacchi G, Cazzaniga ME, Pronzato P, et al. Breast cancer in elderly women: a different reality? Results from the NORA study. Ann Oncol 2007;18:991-996.
69. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-556.
70. Lazovich DA, White E, Thomas DB, Moe RE. Underutilization of breast-conserving surgery and radiation therapy among women with stage I or II breast cancer. JAMA 1991;266:3433-3438.
71. Wyld L, Garg DK, Kumar ID, et al. Stage and treatment variation with age in postmenopausal women with breast cancet: compliance with guidelines. Br J Cancer 2004;90:1486-1491.
72. Kemeny MM, Peterson BL, Komblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-2275.
73. McKeown-Eyssen GE, Rogers-Melamed I, Clarke EA. Estrogen receptor status of breast cancer in Ontario. CMAJ 1985;133:997-1000.
74. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984;2:1102-1109.
75. Eppenberger-Castori S, Moore DH Jr, Thor AD, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002;34:1318-1330.
76. Truong PT, Lee J, Kader HA, et al. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J Cancer 2005;41:1267-1277.
77. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-868.
78. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S1-22; quiz S23-24.
79. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-3852.
80. Fisher CJ, Egan MK, Smith P, et al. Histopathology of breast cancer in relation to age. Br J Cancer 1997;75:593-596.
81. Veronesi U, Cascinelli N, Mariani L, et al. Twenty year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232.
82. Basche M, Byers T. Re: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2001;93:64-65; author reply 65-66.
83. Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer 2004;100:1807-1813.
84. Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg 2005;242:1-6; discussion 7-9.
85. Gennari R, Rotmensz N, Perego E, et al. Sentinel node biopsy in elderly breast cancer patients. Surg Oncol 2004;13:193-196.
86. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-420.
87. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004;91:699-704.
88. Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer 2007;96:1025-1029.
89. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106.
90. Smith BD, Gross CP, Smith GL, et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 2006;98:681-690.
91. Smith BD, Haffty BG, Buchholz TA, et al. Effectiveness of radiation therapy in older women with ductal carcinoma in situ. J Natl Cancer Inst 2006;98:1302-1310.
92. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-1387.
93. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25:3259-3265.
94. Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007;82:265-271.
95. Smith BD, Haffty BG, Hurria A, et al. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol 2006;24:4901-4907.
96. Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev 2007;33:578-593.
97. Morrow M, Mujahid M, Lantz PM, et al. Conelates of breast reconstruction: results from a population-based study. Cancer 2005;104:2340-2346.
98. Joslyn SA. Patterns of care for immediate and early delayed breast reconstruction following mastectomy. Plast Reconstr Surg 2005;115:1289-1296.
99. Lipa JE, Youssef AA, Kuerer HM, et al. Breast reconstruction in older women: advantages of autogenous tissue. Plast Reconstr Surg 2003;111:1110-1121.
100. Bleicher KJ, Topham NS, Morrow M. Beauty and the beast: management of breast cancer after plastic surgery. Ann Surg 2008;247:680-686.
101. Zienowicz RJ, Karacaoglu E. Implant-based breast reconstruction with allograft. Plast Reconstr Surg 2007;120:373-381.
102. Crivellari D, Sun Z, Coates AS, et al. Aromatase inhibitors for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1-98 trial [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 9033.
103. Owusu C, Lash TL, Silliman RA. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer. Breast J 2007;13:374-382.
104. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
105. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092.
106. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271.
107. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-2011.
108. Early Breast Cancer Clinical Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
109. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007;25:3797-3799.
110. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-2746.
111. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-1667.
112. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29-40.
113. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004;22:4622-4630.
114. Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006;24:2757-2764.
115. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-2756.
116. Giordano SH, Pinder MC, Duan Z, et al. Congestive heart failure (CHF) in older women treated with anthracycline chemotherapy [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 521.
117. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007;25:3871-3876.
118. Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2005;92:151-156.
119. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
120. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 1992;268:57-62.
121. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
122. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; San Antonio, Texas; December 14-17, 2006. Abstract 52.
123. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
124. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
125. Smith I, Procter M, Gelber R, Piccart-Gebhart M. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36.
126. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
127. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
128. Geyer CE, Bryant JL, Romond EH, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) vs. ACT with trastuzumab (H) [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 581.
129. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-7819.
130. Takita M, Matsumura T, Kodama Y, et al. Trastuzumab after adjuvant chemotherapy in older patients. Lancet 2007;369:991; author reply 991-992.
131. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-3167.
132. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007;25:292-300.
133. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
134. Dranitsaris G, demons M, Verma S, et al. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005;6:856-863.
135. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972.
136. Theriault RL, Biermann JS, Brown E, et al. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw 2006;4(Suppl 2):S1-20; quiz S21-22.
137. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancel. J Clin Oncol 2003;21:4042-4057.
138. Rodgers GM, Becker PS, Bennett CL, et al. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Treatment-Related Anemia, version 1, 2009. Available at: http://www.nccn.org/professionals/physician_gls. Accessed April 10, 2008.
139. Hurria A. Clinical trials in older adults with cancer: past and future. Oncology (Williston Park) 2007;21:351-358; discussion 363-354, 367.
140. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22:4626-4631.
141. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112-3124.
142. Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 2005;23:2201-2207.
143. Hillner BE, Mandelblatt J. Caring for older women with breast cancer: can observational research fill the clinical trial gap? J Natl Cancer Inst 2006;98:660-661.
144. Berry DA, Ravdin PM. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst 2007;99:1139-1141.